Myeloma Expert Brian Durie Discusses the ASPIRE Trial

Article

Brian G.M. Durie, an expert in multiple myeloma at Cedars-Sinai in Los Angeles, Calif., and chairman of the International Myeloma Foundation, discusses the ASPIRE trial for patients with relapsed myeloma.

Brian G.M. Durie, an expert in multiple myeloma at Cedars-Sinai in Los Angeles, Calif., and chairman of the International Myeloma Foundation, discusses the ASPIRE trial for patients with relapsed myeloma. The study evaluated adding Kyprolis (carfilzomib) to the combination of Revlimid (lenalidomide) and the steroid dexamethasone.

"This was a very important observation just to show the substantial impact of using three drugs versus two drugs," Durie says. "And so using a novel combination of three drugs, you could add basically one year to the remission duration and possibly even longer to the survival of the patient."

Related Videos
Dr. Andrea Apolo in an interview with CURE
Dr. Kim in an interview with CURE
Dr. Nguyen, from Stanford Health, in an interview with CURE
Dr. Barzi in an interview with CURE
Sue Friedman in an interview with CURE
Dr. Giles in an interview with CURE
Related Content